Key Details
Annual ROE
-370.22%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 15, 2021Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 09, 2022Analyst ratings
Recent major analysts updates
28 Aug '23 HC Wainwright & Co.
Neutral10 Apr '23 HC Wainwright & Co.
Buy26 Oct '22 HC Wainwright & Co.
Buy29 Aug '22 HC Wainwright & Co.
Buy02 May '22 HC Wainwright & Co.
Buy31 Mar '22 HC Wainwright & Co.
BuyScreeners with TMBR included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Timber Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
TMBR
Zacks Investment Research22 August 2023
Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.
Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?
TMBR
InvestorPlace21 August 2023
Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is undergoing a massive rally on Monday after announcing that Leo US is acquiring it in a $36 million deal. According to a press release from Timber Pharmaceuticals, that acquisition has an upfront payment of $14 million for TMBR stock.
Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001
TMBR
Zacks Investment Research08 June 2023
Timber (TMBR) receives a dermal carcinogenicity waiver from the FDA for TMB-001, which is being developed to treat moderate-to-severe subtypes of congenital ichthyosis.
Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now
TMBR
Zacks Investment Research14 April 2023
Timber Pharmaceuticals, Inc. (TMBR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
FAQ
- What is the primary business of Timber Pharmaceuticals?
- What is the ticker symbol for Timber Pharmaceuticals?
- Does Timber Pharmaceuticals pay dividends?
- What sector is Timber Pharmaceuticals in?
- What industry is Timber Pharmaceuticals in?
- What country is Timber Pharmaceuticals based in?
- When did Timber Pharmaceuticals go public?
- Is Timber Pharmaceuticals in the S&P 500?
- Is Timber Pharmaceuticals in the NASDAQ 100?
- Is Timber Pharmaceuticals in the Dow Jones?
- When was Timber Pharmaceuticals's last earnings report?
- When does Timber Pharmaceuticals report earnings?
- Should I buy Timber Pharmaceuticals stock now?
What is the primary business of Timber Pharmaceuticals?
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
What is the ticker symbol for Timber Pharmaceuticals?
The ticker symbol for Timber Pharmaceuticals is NYSE American:TMBR
Does Timber Pharmaceuticals pay dividends?
No, Timber Pharmaceuticals does not pay dividends
What sector is Timber Pharmaceuticals in?
Timber Pharmaceuticals is in the Healthcare sector
What industry is Timber Pharmaceuticals in?
Timber Pharmaceuticals is in the Biotechnology industry
What country is Timber Pharmaceuticals based in?
Timber Pharmaceuticals is headquartered in United States
When did Timber Pharmaceuticals go public?
Timber Pharmaceuticals's initial public offering (IPO) was on 08 September 2014
Is Timber Pharmaceuticals in the S&P 500?
No, Timber Pharmaceuticals is not included in the S&P 500 index
Is Timber Pharmaceuticals in the NASDAQ 100?
No, Timber Pharmaceuticals is not included in the NASDAQ 100 index
Is Timber Pharmaceuticals in the Dow Jones?
No, Timber Pharmaceuticals is not included in the Dow Jones index
When was Timber Pharmaceuticals's last earnings report?
Timber Pharmaceuticals's most recent earnings report was on 15 November 2021
When does Timber Pharmaceuticals report earnings?
The date for Timber Pharmaceuticals's next earnings report has not been announced yet
Should I buy Timber Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions